Pharmacology for the gastrointestinal tract

Clinics in Perinatology

Volumn 29, Issue 1, 2002, Pages 115-133

  James, Laura P ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETHANECHOL; CAFFEINE; CISAPRIDE; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DEXAMETHASONE; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; FAMOTIDINE; FENTANYL; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; MORPHINE; OMEPRAZOLE; PROKINETIC AGENT; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANITIDINE; THEOPHYLLINE;

BILE SECRETION; BRADYCARDIA; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSTONIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INTESTINE MOTILITY; LONG QT SYNDROME; NAUSEA; NEWBORN CARE; PARKINSONISM; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RASH; REVIEW; STOMACH ACID SECRETION; STOMACH MOTILITY; SWALLOWING; TORSADE DES POINTES; VERTIGO; VOMITING;

EID: 0036126124     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(03)00067-8     Document Type: Review

References (110)

1. Pepsin and its multiple forms in early life
2. Metoclopramide: Dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy
3. Omeprazole in infants with cimetidine-resistant peptic esophagitis
4. Developmental patterns of renal functional maturation compared in the human neonate
5. Cisapride: A gastrointestinal prokinetic drug
6. Clinical pharmacokinetics of metoclopramide
7. Dystonic reactions and the pharmacokinetics of metoclopramide in children
8. Cisapride: Drug interactions of clinical significance
9. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux
10. Ontogeny of fasting small intestinal motor activity in the human infant
11. Postprandial motor response of the small intestine to enteral feeds in preterm infants
12. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease
13. Mydriatics slow gastric emptying in preterm infants
14. Dystonic reactions with metoclopramide: Is there a risk population?
15. Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases
16. Medical management of gastroesophageal reflux
17. Studies of prematures given erythromycin estolate
18. The effect of oral and intravenous metoclopramide on human lower esophageal sphincter pressure
19. Stress ulcer prophylaxis in the critically ill: A meta-analysis
20. Alteration of normal gastric flora in neonates receiving ranitidine
21. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease
22. Cisapride for gastro-oesophageal reflux and peptic oesophagitis
23. Intestinal absorption of bile salts: Immature development in the neonate
24. Pharmacokinetics of oral midazolam and 1-OH-midazolam in preterm infants
25. Cytochrome P450 3A: Ontogeny and drug disposition
26. Development of gastrointestinal motility in the infant and child
27. Clinical pharmacokinetics of famotidine
28. Use of bethanechol for the treatment of gastroesophageal reflux
29. Cardiac toxicity associated with intravenous erythromycin lactobionate: Two case reports and a review of the literature
30. Erythromycin induced cardiovascular toxicity
31. Ranitidine pharmacokinetics in newborn infants
32. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood
33. Severe upper gastrointestinal bleeding in healthy full-term neonates
34. Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux
35. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children
36. Enteral absorption and bioavailability in children in relation to age
37. Proarrhythmia associated with cisapride in children
38. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: A case review and cohort study
39. Perinatal renal pharmacology
40. Gastric emptying in infants: Response to metoclopramide depends on the underlying condition
41. Tolerance to intravenous ranitidine
42. Pharmacokinetics and pharmacodynamics of famotidine in infants
43. Pharmacokinetics and pharmacodynamics of famotidine in children
44. Long-term use of cisapride (Prepulsid) in premature neonates of less than 34 weeks gestational age
45. A decade of experience with neonatal extracorporeal membrane oxygenation
46. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: Endoscopic healing and twenty-four-hour intragastric acidity
47. Omeprazole disposition in children
48. Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux
49. Metoclopramide-induced methemoglobinemia
50. Cisapride disposition in neonates and infants
51. Pharmacokinetics of metoclopramide in neonates
52. The prophylactic use of ranitidine in babies treated with dexamethasone
53. Gastric acid secretion in preterm infants
54. Effects of cisapride on QT interval in children
55. Effect of cisapride on the QT interval in infants with gastroesophageal reflux
56. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa
57. Long-term gastric pH monitoring for determining optimal dose of ranitidine for critically ill preterm and term neonates
58. Expression of CYP3A in the human liver-evidence that the shift between CYP 3A7 and CYP3A4 occurs immediately after birth
59. Development of lipolytic activity in gastric aspirates from premature infants
60. Bethanechol versus antacids in the treatment of gastroesophageal reflux
61. Digoxin inactivation by the gut flora in infancy and childhood
62. Ranitidine prophylaxis in acute gastric mucosal damage in critically ill pediatric patients
63. High prevalence of asymptomatic esophageal and gastric lesions in preterm infants in intensive care
64. Omeprazole
65. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis
66. Upper and lower gastrointestinal complications with dexamethasone despite H2 antagonists
67. Metoclopramide promotes enteral feeding in preterm infants with feeding intolerance
68. Long-term use of cisapride (Propulsid) in premature neonates
69. Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine
70. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?
71. Acetaminophen elimination kinetics in neonates, children, and adults
72. Antibiotic treatment of neonates-does route of administration matter?
73. Famotidine pharmacokinetics in infants
74. Ranitidine-induced bradycardia in a neonate: A first report
75. Maturation of the lower oesophageal sphincter in the preterm baby
76. Erythromycin treatment for gastrointestinal dysmotility in preterm infants
77. Dexamethasone treatment during ventilator dependency: Possible life threatening gastrointestinal complications
78. Bethanechol for pediatric gastroesophageal reflux: A prospective, blind, controlled study
79. Population pharmacokinetic analysis of oral lansoprazole suspension in pediatric patients
80. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age
81. The penicillins
82. Can prophylactic oral erythromycin reduce time to full enteral feeds in preterm neonates?
83. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage
84. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres
85. Review article: Promotility drugs in the treatment of gastro-oesophageal reflux disease
86. Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: Cisapride and metoclopramide
87. Use of metoclopramide in preterm infants
88. Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig
89. Effects of cisapride on QTc interval in neonates
90. Acute dystonic reaction to bethanechol: A direct acetylcholine receptor agonist
91. The use of cisapride in children
92. Erythromycin in neonatal postoperative intestinal dysmotility
93. Early effects of bethanechol on the esophageal motor function of infants with gastroesophageal reflux
94. Influence of erythromycin on establishment of feeding in preterm infants: Observations from a randomised controlled trial
95. Results of treatment of gastroesophageal reflux with bethanechol
96. Effect of ranitidine on twenty-four-hour gastric acidity in infants
97. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy
98. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants
99. Antroduodenal manometry in children with no upper gastrointestinal symptoms
100. Drug interactions with proton pump inhibitors
101. Gastroesophageal reflux incidence and respiratory dysfunction during sleep in infants: Treatment with cisapride
102. Cisapride decreases prolonged episodes of reflux in infants
103. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection
104. Cisapride: A survey of the frequency of use and adverse events in premature newborns
105. Bile-salt metabolism in the newborn: Measurement of pool size and synthesis by stable isotope technic
106. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation
107. Pharmacokinetics of ranitidine in critically ill infants
108. Methemoglobinemia following metoclopramide therapy in an infant
109. Cisapride and fatal arrhythmia
110. Single-dose pharmacokinetics and bioavailability of famotidine in man: Results of multicenter collaborative studies